What do systematic reviews say?

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.13 [0.47, 2.71]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ treated with an… compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.2 [0.41, 3.51]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ not treated with an… compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1 [0.22, 4.56]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.93 [0.61, 1.42]
  2 studies · 945 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.86 [0.64, 1.15]
  3 studies · 1019 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 1.04 [0.75, 1.45]
  5 studies · 1187 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 154 participants
  Low